A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.
about
Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing ActivityHuman Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus MacaquesNeutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptorSurvivors Remorse: antibody-mediated protection against HIV-1.Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV InfectionWhich Antibody Functions are Important for an HIV Vaccine?New paradigms for functional HIV-specific nonneutralizing antibodiesThe role of Fc receptors in HIV infection and vaccine efficacy.Neutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an FcγRIIa independent mechanism and do not diminish cytokines production.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesBroadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activityAnalysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: An update for 2011-2012.Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systemsMABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicideExploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge.Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants.Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice.Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.Neutralizing antibodies to HIV-1 induced by immunization.Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques.Opportunities to exploit non-neutralizing HIV-specific antibody activity.The role of Fc receptors in HIV prevention and therapy.Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies.Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challengeEpitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses.Comparison of antibodies that mediate HIV type 1 gp120 antibody-dependent cell-mediated cytotoxicity in asymptomatic HIV type 1-positive men and women.Non-neutralizing antibodies in prevention of HIV infection.HIV-specific antibody-dependent cellular cytotoxicity: a novel vaccine modality.Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).Role of Fc-mediated antibody function in protective immunity against HIV-1.A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome.Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV.Engineering broadly neutralizing antibodies for HIV prevention and therapy.Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.
P2860
Q26782237-DD21E5D0-CD10-4C59-8602-1D9AD0E818B6Q27318266-5786DBB7-CCC4-4538-8E6F-D4592817E6CCQ27318508-EB9E0EEA-B150-431B-A232-46F64CCCA597Q27684529-4A9E9FD3-0E1B-4892-8344-E117C071258BQ30238730-30FCA808-1695-4358-89B8-9F84AC3849DBQ33620546-E5E70707-FF6B-40BB-82E8-BE05AF4E0BD3Q33772637-3E2B0D40-D979-4FFA-8C70-E122989F5F71Q33900595-50C76A38-3CD4-43E4-B192-726F69BAA254Q33997395-78078842-2439-4834-B4B7-1CE06CFB1171Q34055377-F1E992E6-BEFD-4922-B527-0DA3BEEA1AD1Q34057711-11250841-F487-4793-A4BF-6221160F26D3Q34204325-09B38416-7CE6-4942-BB6A-3BFFD48F4F10Q34489424-904DDD47-E7AD-4985-A18A-2AAB0DF9AC56Q34637663-BFB4B6B9-F1AC-4C24-84FE-D303B383565DQ34784621-E57D881D-E232-4AB4-BAE9-D6317FAA761CQ34869927-9364904D-9CD2-41F1-91DC-39B5312794EEQ34974016-B99C5DDC-DB43-454E-9768-8E9A654CA9E6Q35569901-ABAEF6BF-E164-478B-B0A4-344351391787Q36179265-D9D6A796-2D84-4313-9336-879D33FD44BAQ36414891-BDBF67F2-1A19-4AA4-91D4-E4B7667FC9C7Q36440069-44BA0DF8-B873-4C03-BD4A-E6C2008850DDQ36515149-3F8BEC88-718D-47C2-B084-069C33976399Q36603515-01C8B0DF-743B-484C-9668-D898EAAA3B1DQ37002517-0974562B-5E10-40B0-B9AC-015FC42F4949Q37025857-5AF34A1C-9CFA-4A35-AB59-639214721138Q37113941-26D5DCAA-1426-4DDE-A3E2-B10B095F68AAQ37113972-32BE8EAA-CC4D-4D0B-81DF-606F8F6C748FQ37184296-E483696B-3EDB-4FCC-A9FD-7B35CF1FC4A5Q37252676-F886C3DB-BC13-4F84-95C1-DDE0D52F487AQ37426168-3E853747-45A6-43CF-9866-C4800C8D621EQ37460091-312A7E35-83EC-4426-A980-82CFCD9F25C2Q38058120-2955D53E-ACCE-4F5A-96DC-D0516B76ABC6Q38061191-F6B1FCA9-5099-47AF-88BB-072124A8308EQ38072056-6EE18CF4-855E-4EF3-85B0-05AD082D2F0CQ38206519-1C376518-66F4-470E-899B-9EAD1A4F7A98Q38213061-68B411FD-1B2C-49B8-9919-796C71727AB2Q38542411-88F658F0-3950-4CFA-9A28-E3F13AC60907Q38688524-55FFDF01-8B2E-48E3-A051-AAA35A77B787Q38717198-BAA88791-AD3A-4729-9291-38982B5BF754Q38727815-49469AD6-8520-4033-86AE-3CE5A6B006C9
P2860
A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A nonfucosylated variant of th ...... al SHIV challenge in macaques.
@ast
A nonfucosylated variant of th ...... al SHIV challenge in macaques.
@en
type
label
A nonfucosylated variant of th ...... al SHIV challenge in macaques.
@ast
A nonfucosylated variant of th ...... al SHIV challenge in macaques.
@en
prefLabel
A nonfucosylated variant of th ...... al SHIV challenge in macaques.
@ast
A nonfucosylated variant of th ...... al SHIV challenge in macaques.
@en
P2093
P2860
P50
P356
P1433
P1476
A nonfucosylated variant of th ...... al SHIV challenge in macaques.
@en
P2093
Ann J Hessell
Anne-Sophie Dugast
Brian Moldt
Chenggang Jin
D Cameron Dunlop
David T Evans
Dennis R Burton
Donald N Forthal
Eva G Rakasz
Galit Alter
P2860
P304
P356
10.1128/JVI.00491-12
P407
P577
2012-03-28T00:00:00Z